Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
TDOC expands Solo with AI tools that streamline virtual assessments and clinical documentation, targeting simpler workflows for hospitals.
TDOC - Teladoc Health, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$8.83
DETAILS
HIGH:
$11.00
LOW:
$7.50
MEDIAN:
$8.00
CONSENSUS:
$8.83
UPSIDE:
53.03%
Stock News
Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Teladoc (TDOC) settling at $5.56, representing a -3.64% change from its previous close.
Stock Picks From Seeking Alpha's September 2026 New Analysts
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.
Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery
New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows
Head to Head Survey: National Research (NASDAQ:NRC) vs. Teladoc Health (NYSE:TDOC)
Teladoc Health (NYSE: TDOC - Get Free Report) and National Research (NASDAQ: NRC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares Teladoc
Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Teladoc (TDOC) reached $5.75 at the closing of the latest trading day, reflecting a -2.38% change compared to its last close.
171,447 Teladoc Health, Inc. $TDOC Shares Sold by Corient Private Wealth LP
Corient Private Wealth LP trimmed its holdings in shares of Teladoc Health, Inc. (NYSE: TDOC) by 62.8% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 101,556 shares of the health services provider's stock after selling 171,447 shares during the period. Corient Private Wealth LP owned
Teladoc Health Announces Chief Legal Officer Transition
Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026
Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note
Teladoc (TDOC) closed the most recent trading day at $6.13, moving 3.46% from the previous trading session.
Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade
Teladoc (TDOC) concluded the recent trading session at $6.28, signifying a -2.33% move from its prior day's close.
Teladoc: Integrated Care And Free Cash Flow Could Bring It Back To Life
Teladoc Health trades near multi-year lows, with the market pricing in deep distress despite meaningful free cash flow and manageable debt. BetterHelp's rapid decline drags on TDOC, but Integrated Care's improving margins and growing revenue per member offer stabilization. TDOC's valuation is extremely depressed, trading at just 7–8x expected free cash flow, with fair value estimates suggesting significant upside even under conservative scenarios.
Why Teladoc (TDOC) Outpaced the Stock Market Today
Teladoc (TDOC) reached $6.16 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.
Dow, Nasdaq Down Triple Digits as Brent Crude Tops July Peak
Major Indexes are moving lower once again as investors focus on geopolitical tensions
2 Beaten-Down Stocks to Avoid Right Now
Don't catch a falling knife.
Here's Why Teladoc's Integrated Care Business Deserves More Attention
TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee.
Here's Why Investors Should Stay Neutral on TDOC Stock for Now
Teladoc Health's growth is supported by chronic care, international expansion and Teladoc One, but BetterHelp weakness and losses temper the outlook.
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 87,511 Teladoc Health, Inc. $TDOC
Connor Clark and Lunn Investment Management Ltd. bought a new position in Teladoc Health, Inc. (NYSE: TDOC) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,511 shares of the health services provider's stock, valued at approximately $742,000. Several other hedge funds
Teladoc appoints insurance executive Michael Grasher as CFO
Teladoc Health said on Monday it appointed Michael Grasher as its chief financial officer, bringing in an industry veteran to help the virtual healthcare company navigate rising demand for its insurance-covered business.
Teladoc Health Appoints Michael Grasher as Chief Financial Officer
Appointment brings seasoned financial leadership as Teladoc Health advances its strategy aimed at delivering disciplined, sustainable growth NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Michael Grasher as Chief Financial Officer, effective immediately. Mr. Grasher is an accomplished financial executive with more than three decades of experience across the insurance and financial services sectors, including more than 12 years in CFO roles at public and privately held companies.
Price Targets
Teladoc price target lowered to $8 from $9 at Jefferies
$8.00
(was $6.72)
Brian Tanquilut
·
Jefferies
Teladoc price target lowered to $7.50 from $10 at Evercore ISI
$7.50
(was $6.71)
Evercore ISI
Teladoc price target raised to $11 from $10 at Canaccord
$11.00
(was $9.65)
Richard Close
·
Canaccord Genuity
Teladoc price target raised to $6 from $5 at Evercore ISI
$6.00
(was $5.27)
Evercore ISI
Deutsche Bank Upgrades Teladoc (TDOC) to Buy
$11.00
(was $5.58)
George Hill
·
Deutsche Bank
Teladoc (TDOC) PT Lowered to $6 at Stifel Following Q4 Results
$6.00
(was $5.07)
David Grossman
·
Stifel Nicolaus
Teladoc (TDOC) PT Lowered to $6 at Wells Fargo
$6.00
(was $4.65)
Stephen Baxter
·
Wells Fargo
Teladoc price target lowered to $8 from $9 at Goldman Sachs
$8.00
(was $6.53)
Goldman Sachs
Teladoc price target lowered to $9 from $10 at Goldman Sachs
$9.00
(was $7.61)
David Roman
·
Goldman Sachs
Teladoc initiated with an Equal Weight at Barclays
$8.50
(was $7.56)
Barclays
Stifel Reiterates Hold Rating on Teladoc (TDOC)
$8.00
(was $8.82)
David Grossman
·
Stifel Nicolaus
Teladoc price target lowered to $10 from $12 at Cantor Fitzgerald
$10.00
(was $7.40)
Raymond James
Teladoc (TDOC) PT Raised to $13 at Piper Sandler
$13.00
(was $11.01)
Jessica Tassan
·
Piper Sandler
Teladoc (TDOC) PT Raised to $11 at Citi
$11.00
(was $8.86)
Daniel Grosslight
·
Citigroup
Evercore ISI Reiterates In Line Rating on Teladoc (TDOC)
$9.00
(was $8.86)
Elizabeth Anderson
·
Evercore ISI
Teladoc price target lowered to $10 from $25 at Piper Sandler
$10.00
(was $7.60)
Jessica Tassan
·
Piper Sandler
Barclays Reiterates Overweight Rating on Teladoc (TDOC)
$20.00
(was $10.48)
Steve Valiquette
·
Barclays
Teladoc (TDOC) PT Lowered to $10 at Jefferies, 'Shares Ripen for Activism'
$10.00
(was $11.29)
Glen Santangelo
·
Jefferies
Teladoc price target lowered to $14 from $16 at Jefferies
$14.00
(was $12.39)
Glen Santangelo
·
Jefferies
Teladoc (TDOC) PT Lowered to $18 at Deutsche Bank
$18.00
(was $14.64)
George Hill
·
Deutsche Bank